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Volume 53, Number 1 Abstracts 259The State of Endovenous Ablation for Venous Insufficiency in Florida
M. S. Hong, K. Butler, T. D. Fischer, and P. R. Nelson, University of
Florida, Gainesville, Fla
Background: Endovenous ablation has recently been adopted for
treatment of lower extremity venous insufficiency. We sought to define the
current trends in the use of endovenous procedures and the impact on the
associated costs in the state of Florida (Fig).
Methods: The Agency for Healthcare Administration database,
which contains 100% of encounters from ambulatory centers in Florida,
was queried for endovenous laser or radiofrequency ablation procedures,
using Current Procedural Technology codes 36478 and 36475, respec-
tively, for the study period of Q1 of 2005 to Q3 of 2008. International
Classification of Diseases-9 diagnostic codes were used to identify sever-
ity of the venous disease. The main measures included type of ablation,
provider specialty, and total charges. A comparison of practice patterns
and associated charges were performed for the two main provider groups,
namely general/vascular surgeons (GS/VS) and diagnostic/interven-
tional radiologists (DR/IR).
Results: Our query consisted of 4,143 encounters during the study
period. The mean age was 54  13 years, and 73% were women.
Compared with the Florida population, white and white-Hispanic race
was over-represented (91.4% vs Florida 81%), and black race was under-
represented (4.3% vs Florida 16%). The most common complaint was
edema, pain, or swelling (45.5%), followed by varicose veins with inflam-
mation (17.8%), unspecified venous insufficiency (12.6%), asymptomatic
varicose veins (11.9%), and phlebitis/thrombophlebitis (10.2%). Laser
ablation outnumbered radiofrequency ablation each year (mean 697 vs
416 per year, respectively). Vascular and general surgeons comprised the
vast majority of providers, consisting of 48.7% and 40.9% of encounters,
respectively. Other providers of note include cardiothoracic surgeons
(1.2%) and DR/IR (3.8%). In total, 21 specialties were represented.
GS/VS providers performed secondary ablations in 32.5% encounters,
and stab phlebectomies in 18.2%. In contrast, DR/IR performed second-
ary ablations in only 3.8%, and stab phlebectomy in 5.1%. Total charges
overall were $11,644  $6,682; $11,696  6,594 for GS/VS and
$6,392  4,820 for DR/IR. Most of this difference was due to charges
related to the operating room ($7,858 GS/VS and $3,944 DR/IR),
likely reflecting differences in practice patterns.
Table I. Ultrasound result on 59 completed legs
Venous
status
3 years above
knee n (%)
Group surgery (n 
26)
1 17 (65.4)
2 2 (7.7)
3 7 (26.9)
Group foam (n  33) 1 16 (48.5)
2 6 (18.2)
3 11 (33)
Mann-Whitney U test P P  .298Venous status: 1, occluded; 2, competent; 3, reflux.Conclusions: Endovenous ablation offers a minimally invasive op-
tion for treatment of venous insufficiency. Although providers span a
wide range of specialties, the majority of endovenous ablations per-
formed in ambulatory centers are performed by general or vascular
surgeons. GS/VS performed substantially more secondary procedures
compared with DR/IR, resulting in higher total charges. More studies
are required to determine whether this disparity in practice patterns result
in different outcomes.
Randomized Controlled Trial of Ultrasound Guided Foam Sclerother-
apy Combined with Sapheno-Femoral Ligation Compared to Surgical
Treatment of Varicose Veins: Five-year Results
E. Kalodiki,a M. Azzam,b C. R. Lattimer,a E. Shawish,b N. Zambas,b and G.
Geroulakosa, The Ealing Hospital and Imperial College London, London,
United Kingdom,a and the Ealing Hospital, Middlesex, United Kingdom.b
Background: Up to 5-year results of a prospective randomized con-
trolled trial comparing foam sclerotherapy and surgery to standard surgery,
in patients with primary varicose veins.
Methods: Seventy-three patients (82 legs) underwent sapheno-femo-
ral ligation, stripping, and multiple phlebectomies under general anesthesia
(n  39; M:F, 16:23; mean age, 47 years [range, 23-76 years]; group S) or
sapheno-femoral ligation under local anesthesia and concurrent sclerother-
apy (n 43;M:F, 11:32; mean age, 49 years [range, 26-42 years]; group F).
Assessments included CEAP classification, ultrasound, Venous Clinical Se-
verity Score (VCSS), Aberdeen Varicose Vein Questionnaire (AVVQ), and
Short Form 36 (SF36) scores.
Results: CEAP was similar between groups, C2-6. On the 59 legs with
completed ultrasound, reflux at 3 to 5 years is presented (Table I).
In group S, 40% of legs required 25 additional foam sessions with a
mean volume of 11 mL and a total volume of 154 mL. In group F, 47.5% of
legs required 33 additional sessions with a mean volume of 9 mL and a total
volume of 207 mL. Preoperatively the VCSS score was equivalent between
the two groups (median-range-Interquartile Range [IQR]; group S: 5,
3-12, 3 and group F: 4.5, 2-15, 2; P  .359 Mann-Whitney U test).
However, after treatment there was improvement within both groups (me-
dian-range-IQR for group S: 1, 0-9, 5; P .001; for group F: 1, 0-9, 2; P
.0005Wilcoxon). Changes in VCSS before and at 3 years (P .504) and the
absolute VCSS scores (P  .313) were similar between both groups. The
Venous Disease Severity Score (VSDS) score improved in both groups due
to treatment (Table II).
The AVVQ score also improved within both groups (median-
interquartile range preoperatively vs 3 years [S: 16.32-4.7 vs 8.94-11.51;
P  .003; F: 12.28-10.37 vs 4.97-6.19; P  .0005 Wilcoxon). The
improvement on the AVVQ score before and after treatment was similar
5 years above
knee n (%)
3 years below
knee n (%)
5 years below
knee n (%)
14 (53.8) 6 (23.1) 10 (38.5)
3 (11.5) 6 (23.1) 7 (26.9)
9 (34.6) 14 (53.8) 9 (34.6)
19 (57.6) 15 (45.5) 8 (24.2)
1 (3.0) 4 (12.1) 11 (33.3)
13 (39.4) 14 (42.4) 14 (42.4)
P  .194 P  1.000 P  .341
Table II. Venous Clinical Severity Score up to 5 years
between groups on 70 patients
Group surgery
median
(IQR)
Group foam
median
(IQR)
Mann-Whitney
U Test
Pretreatment 1.0 (1.3) 1.0 (1.0) P  .518
3 years 0.5 (1.0) 1.0 (1.0) P  .780
5 years 1.0 (1.0) 0.25 (1.0) P  .388
Friedman P  .0005 P  .0005
